drugset
drugset / Trial / NCT05826535

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

NCT05826535 ↗

Phase 1/2 Recruiting 270 enrolled Lyell Immunopharma, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.

Timeline

Start
2023-05-09
Primary completion
2028-12-31
Completion
2031-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Rondecabtagene autoleucel Cell therapy — Intravenous
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

large B-cell lymphoma non-Hodgkin lymphoma